Hoth Therapeutics (NASDAQ:HOTH) Shares Up 3.3%

Hoth Therapeutics, Inc. (NASDAQ:HOTH)’s share price traded up 3.3% on Thursday . The stock traded as high as $1.25 and last traded at $1.23. 29,292 shares changed hands during trading, a decline of 92% from the average session volume of 371,291 shares. The stock had previously closed at $1.19.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $4.00 price objective on shares of Hoth Therapeutics in a research note on Friday, April 5th.

Hoth Therapeutics Stock Performance

The firm has a 50 day moving average price of $1.29 and a 200 day moving average price of $1.28.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.